title: Etanercept, adalimumab, and ustekinumab in psoriasis: analysis of 209 treatment series in Austria.
abstract: OBJECTIVE
  Widely used in the treatment of psoriasis, biologics have been tested in numerous clinical trials. However, drug efficacies and adverse events (AEs) may differ in 'real-world' patients as they do not undergo as rigorous selection and monitoring. Our objective was to examine drug survival, efficacy, and AEs (quality, time of onset) in 'real-world' psoriasis patients treated with etanercept, adalimumab, and ustekinumab.
  
  
  METHODS
  Retrospective data analysis (Jan 1, 2004 to Jun 30, 2015) of patients treated at a psoriasis clinic in an Austrian hospital. All patients who had received at least one dose of etanercept, adalimumab, or ustekinumab were included in the analysis. We analyzed: demographics, drug survival, Psoriasis Area and Severity Index (PASI), as well as quality and time of onset of AEs.
  
  
  RESULTS
  In 209 treatment series, the estimated median drug survival varied among the various treatments: 21 months (SE: 6.9) for etanercept, 61 months (SE: 9.4) for adalimumab, and 65 months (SE 1.4) for ustekinumab. Male gender and pretreatment with a biologic were positive predictors of longer drug survival in adalimumab. We found no significant difference in drug efficacy as determined by PASI.
  
  
  CONCLUSIONS
  Most AEs occur during the first year of treatment. Adalimumab and ustekinumab are marked by longer drug survival compared to etanercept.
authors.affiliation: Rudolfstiftung Hospital, Department of Dermatology, Vienna, Austria.
authors.forename: Leo
authors.initials: L
authors.lastname: Richter
authors.affiliation: Rudolfstiftung Hospital, Department of Dermatology, Vienna, Austria.|School of Medicine, Sigmund Freud University Vienna, Austria.
authors.forename: Igor
authors.initials: I
authors.lastname: Vujic
authors.affiliation: Rudolfstiftung Hospital, Department of Dermatology, Vienna, Austria.
authors.forename: Alma
authors.initials: A
authors.lastname: Sesti
authors.affiliation: Rudolfstiftung Hospital, Department of Dermatology, Vienna, Austria.
authors.forename: Babak
authors.initials: B
authors.lastname: Monshi
authors.affiliation: Department of Medical Sciences, Section of Dermatology, University of Turin, Italy.
authors.forename: Martina
authors.initials: M
authors.lastname: Sanlorenzo
authors.affiliation: Rudolfstiftung Hospital, Department of Dermatology, Vienna, Austria.|School of Medicine, Sigmund Freud University Vienna, Austria.
authors.forename: Christian
authors.initials: C
authors.lastname: Posch
authors.affiliation: Rudolfstiftung Hospital, Department of Dermatology, Vienna, Austria.
authors.forename: Klemens
authors.initials: K
authors.lastname: Rappersberger
mesh_terms: D000068879:Adalimumab / Q000008:administration & dosage*; D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001317:Austria / Q000453:epidemiology; D002648:Child; D003879:Dermatologic Agents / Q000008:administration & dosage; D000068800:Etanercept / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011565:Psoriasis / Q000188:drug therapy* / Q000453:epidemiology*; D012189:Retrospective Studies; D012307:Risk Factors; D017678:Sex Distribution; D016896:Treatment Outcome; D000069549:Ustekinumab / Q000008:administration & dosage*; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept